<DOC>
	<DOCNO>NCT00687934</DOCNO>
	<brief_summary>An open-label dose escalation study patient solid tumor treat STA-9090 ( ganetespib )</brief_summary>
	<brief_title>Study STA-9090 , Administered Once-Weekly Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients must document refractory candidate current approve therapy . Must ECOG status 02 . Peripheral neuropathy &lt; = 2 . Must acceptable organ marrow function per protocol parameter . No clinically significant ventricular arrythmias ischemia . Must pregnant breastfeeding . Chemotherapy radiation within 3 week . Previous radiation &gt; 25 % total bone marrow . Previous high dose chemotherapy autologous allogeneic hematopoietic stem cell transplantation . Primary brain tumor active brain metastasis . Use investigational agent within 4 week . Treatment chronic immunosuppressant . Uncontrolled , intercurrent illness .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>metastatic cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>histologically cytologically confirm non-hematological</keyword>
	<keyword>malignancy metastatic unresectable</keyword>
	<keyword>standard therapy exists</keyword>
	<keyword>STA-9090</keyword>
	<keyword>ganetespib</keyword>
</DOC>